Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

633 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma.
Smith MR, Jegede O, Martin P, Till B, Parekh S, Yang DT, Hsi ED, Witzig TE, Dave SS, Scott DW, Hanson CA, Kostakoglu L, Abdel Samad NN, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum K, Romer M, Inwards DJ, Lerner R, Wagner L, Little RF, Friedberg JW, Leonard JP, Kahl BS. Smith MR, et al. Among authors: parekh s. Blood. 2024 May 31:blood.2024023962. doi: 10.1182/blood.2024023962. Online ahead of print. Blood. 2024. PMID: 38820500
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M, Ortiz M, Maciag P, Peluso T, Parekh S, van de Donk NWCJ, Lonial S, Thakurta A. Amatangelo M, et al. Among authors: parekh s. Cell Rep Med. 2024 May 15:101571. doi: 10.1016/j.xcrm.2024.101571. Online ahead of print. Cell Rep Med. 2024. PMID: 38776914 Free article.
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs AP, Kelly G, Patel M, Kim-Schulze S, Flynt E, Lagana A, Gooding S, Merad M, Jagganath S, Pierceall WE, Oppermann U, Thakurta A, Parekh S. Van Oekelen O, et al. Among authors: parekh s. Cell Rep Med. 2024 May 17:101584. doi: 10.1016/j.xcrm.2024.101584. Online ahead of print. Cell Rep Med. 2024. PMID: 38776911 Free article.
Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma.
Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum CA, Pearse R, Jayabalan DS, Gordillo CA, Chan HT, Yamshon S, Thibaud S, Mapara MY, Inghirami GG, Lentzsch S, Reshef R, Rossi A, Parekh S, Jagannath S, Richard S, Niesvizky R, Bustoros M. Mejia Saldarriaga M, et al. Among authors: parekh s. Blood Adv. 2024 May 22:bloodadvances.2023012470. doi: 10.1182/bloodadvances.2023012470. Online ahead of print. Blood Adv. 2024. PMID: 38776397
633 results